BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2025 9:41:56 AM | Browse: 19 | Download: 2
 |
Received |
|
2025-05-21 06:09 |
|
Peer-Review Started |
|
2025-05-22 00:06 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-06-06 03:28 |
|
Revised |
|
2025-06-14 18:39 |
|
Second Decision |
|
2025-08-06 02:35 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-08-06 04:08 |
|
Articles in Press |
|
2025-08-06 04:08 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-09-03 01:00 |
|
Publish the Manuscript Online |
|
2025-09-11 09:41 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Editorial |
| Article Title |
Targeting Ras homolog enriched in brain 1 to restore β-cell mass and function: A potential therapeutic strategy for diabetes
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yao Peng, Dong-Dong Zhang, Ling Gan and Jia-Qi Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Hubei Provincial Natural Science Foundation |
2025AFB845 |
| Graduate Innovation and Entrepreneurship Fund of Wuhan University of Science and Technology |
JCX2024044 |
|
| Corresponding Author |
Jia-Qi Zhang, Associate Professor, MD, PhD, Department of Ultrasound Imaging, Postgraduate Union Training Base of Xiangyang No. 1 People’s Hospital, School of Medicine, Wuhan University of Science and Technology, No. 15 Jiefang Road, Fancheng District, Xiangyang 441000, Hubei Province, China. 347235272@qq.com |
| Key Words |
Diabetes mellitus; β cell dysfunction; Ras homolog enriched in brain 1; Mechanistic target of rapamycin complex 1 pathway; AMP-activated protein kinase pathway; Hepatocyte nuclear factor 4 alpha |
| Core Tip |
Dysregulation of β-cell mass and function contributes to the development and progression of diabetes mellitus. In a recent study, Yang et al identified Ras homolog enriched in brain 1 (Rheb1) as a critical regulator of β-cell proliferation via both mechanistic target of rapamycin complex 1 and AMP-activated protein kinase signaling pathways. Rheb1 also enhances hepatocyte nuclear factor 4 alpha expression, further supporting its role in maintaining β-cell functionality. These results reveal an intricate signaling network through by Rheb1 supports β-cell growth and survival, highlighting its potential as a therapeutic target for diabetes management. Further research is warranted to explore the translational applications of these findings. |
| Publish Date |
2025-09-11 09:41 |
| Citation |
<p>Peng Y, Zhang DD, Gan L, Zhang JQ. Targeting Ras homolog enriched in brain 1 to restore β-cell mass and function: A potential therapeutic strategy for diabetes. <i>World J Diabetes</i> 2025; 16(9): 109768</p> |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i9/109768.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i9.109768 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
